5-{2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride hydrate (BioDeep_00001028655)
代谢物信息卡片
5-{2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride hydrate
化学式: C21H24Cl2N4O2S (466.0996944)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: [H+].C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54.O.[Cl-]
InChI: 1H
描述信息
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents
D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists
D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants
同义名列表
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Marco Pozzi, Chiara Vantaggiato, Francesca Brivio, Genny Orso, Maria Teresa Bassi. Olanzapine, risperidone and ziprasidone differently affect lysosomal function and autophagy, reflecting their different metabolic risk in patients.
Translational psychiatry.
2024 Jan; 14(1):13. doi:
10.1038/s41398-023-02686-x. [PMID: 38191558] - Ankita Sahu, Shaban Ahmad, Khalid Imtiyaz, Ajeeshkumar Kizhakkeppurath Kumaran, Mojahidul Islam, Khalid Raza, Murugesh Easwaran, Asha Kurukkan Kunnath, Moshahid A Rizvi, Saurabh Verma. In-silico and in-vitro study reveals ziprasidone as a potential aromatase inhibitor against breast carcinoma.
Scientific reports.
2023 10; 13(1):16545. doi:
10.1038/s41598-023-43789-1. [PMID: 37783782] - Hannah M Ficarino, Michael Z Caposole, S Noelle Davis, Mackenzie N Krebsbach, Emily F McGowin, Kaitlin M Alexander, Christopher M Kinnard, Jon D Simmons. Neuroleptic Malignant Syndrome: A Potential Etiology of Multisystem Organ Failure in a Burn Patient.
The American surgeon.
2022 Mar; 88(3):519-520. doi:
10.1177/0003134820945245. [PMID: 32988244] - Yub Raj Sedhai, Alok Atreya, Prabin Phuyal, Soney Basnyat, Sagar Pokhrel. Case Report: Ziprasidone induced neuroleptic malignant syndrome.
F1000Research.
2021; 10(?):124. doi:
10.12688/f1000research.51094.1. [PMID: 33763203] - Javier Vázquez-Bourgon, Miguel Ibáñez Alario, Jacqueline Mayoral-van Son, Marcos Gómez Revuelta, Rosa Ayesa Arriola, María Juncal Ruiz, Víctor Ortiz-García de la Foz, Benedicto Crespo Facorro. A 3-year prospective study on the metabolic effect of aripiprazole, quetiapine and ziprasidone: A pragmatic clinical trial in first episode psychosis patients.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology.
2020 10; 39(?):46-55. doi:
10.1016/j.euroneuro.2020.08.009. [PMID: 32891516] - Margo R Rollins, Judith Deeter, Charlene D Banks, Pam Langley. New onset metabolic derangement in a pediatric patient receiving therapeutic plasma exchange for anti-NMDA receptor encephalitis.
Journal of clinical apheresis.
2020 Apr; 35(2):125-127. doi:
10.1002/jca.21768. [PMID: 32027046] - Urooj A Khan, Uzma Parveen, Nazeer Hasan, Mohammad Zubair Ahmed, Suma Saad, Farhan J Ahmad, Gaurav K Jain. Parenteral Sustained Release Lipid Phase-Transition System of Ziprasidone: Fabrication and Evaluation for Schizophrenia Therapy.
Drug design, development and therapy.
2020; 14(?):2237-2247. doi:
10.2147/dddt.s247196. [PMID: 32606594] - Tamara N Uzelac, Aleksandra L Nikolić-Kokić, Snežana D Spasić, Mirjana T Mačvanin, Milan R Nikolić, Ljuba M Mandić, Vesna B Jovanović. Opposite clozapine and ziprasidone effects on the reactivity of plasma albumin SH-group are the consequence of their different binding properties dependent on protein fatty acids content.
Chemico-biological interactions.
2019 Sep; 311(?):108787. doi:
10.1016/j.cbi.2019.108787. [PMID: 31400341] - Tahlia R Meola, Tahnee J Dening, Clive A Prestidge. Nanocrystal-silica-lipid hybrid particles for the improved oral delivery of ziprasidone in vitro.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
2018 Aug; 129(?):145-153. doi:
10.1016/j.ejpb.2018.05.028. [PMID: 29857135] - Anna Dietrich-Muszalska, Jolanta Kolińska-Łukaszuk. Comparative effects of aripiprazole and selected antipsychotic drugs on lipid peroxidation in plasma.
Psychiatry and clinical neurosciences.
2018 May; 72(5):329-336. doi:
10.1111/pcn.12631. [PMID: 29280533] - Javier Vázquez-Bourgon, Rocío Pérez-Iglesias, Víctor Ortiz-García de la Foz, Paula Suárez Pinilla, Álvaro Díaz Martínez, Benedicto Crespo-Facorro. Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-naïve patients with a first-episode of non-affective psychosis.
Psychopharmacology.
2018 01; 235(1):245-255. doi:
10.1007/s00213-017-4763-x. [PMID: 29075885] - Benedicto Crespo-Facorro, Victor Ortiz-Garcia de la Foz, Paula Suarez-Pinilla, Elsa M Valdizan, Rocío Pérez-Iglesias, Jose Antonio Amado-Señaris, M Teresa Garcia-Unzueta, Javier Labad, Christopher Correll, Rosa Ayesa-Arriola. Effects of aripiprazole, quetiapine and ziprasidone on plasma prolactin levels in individuals with first episode nonaffective psychosis: Analysis of a randomized open-label 1year study.
Schizophrenia research.
2017 11; 189(?):134-141. doi:
10.1016/j.schres.2017.01.046. [PMID: 28223031] - Shao-Ting Wang, Yan Li. Development of a UPLC-MS/MS method for routine therapeutic drug monitoring of aripiprazole, amisulpride, olanzapine, paliperidone and ziprasidone with a discussion of their therapeutic reference ranges for Chinese patients.
Biomedical chromatography : BMC.
2017 Aug; 31(8):. doi:
10.1002/bmc.3928. [PMID: 28054367] - Huai-Hai Wang, Min Cai, Hua-Ning Wang, Yun-Chun Chen, Rui-Guo Zhang, Ying Wang, Grainne M McAlonan, Yuan-Han Bai, Wen-Jun Wu, Li Guo, Ya-Hong Zhang, Qing-Rong Tan, Zhang-Jin Zhang. An assessor-blinded, randomized comparison of efficacy and tolerability of switching from olanzapine to ziprasidone and the combination of both in schizophrenia spectrum disorders.
Journal of psychiatric research.
2017 02; 85(?):59-65. doi:
10.1016/j.jpsychires.2016.11.002. [PMID: 27837658] - Tahnee J Dening, Shasha Rao, Nicky Thomas, Clive A Prestidge. Silica encapsulated lipid-based drug delivery systems for reducing the fed/fasted variations of ziprasidone in vitro.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
2016 Apr; 101(?):33-42. doi:
10.1016/j.ejpb.2016.01.010. [PMID: 26812284] - Aleksandra Nikolić-Kokić, Ana Mijušković, Nikola Tatalović, Jelena Nestorov, Marko Miler, Zorana Oreščanin-Dušić, Milan Nikolić, Verica Milošević, Duško Blagojević, Mihajlo Spasić, Čedo Miljević. Effects of antipsychotic drug administration on antioxidative defense enzymes in male rat kidney.
Journal of toxicology and environmental health. Part A.
2016; 79(20):905-11. doi:
10.1080/15287394.2016.1201706. [PMID: 27644343] - Hriday Bera, Shashank Boddupalli, Amit Kumar Nayak. Mucoadhesive-floating zinc-pectinate-sterculia gum interpenetrating polymer network beads encapsulating ziprasidone HCl.
Carbohydrate polymers.
2015 Oct; 131(?):108-18. doi:
10.1016/j.carbpol.2015.05.042. [PMID: 26256166] - Joseph W Iskandar, John Eric Vance, Anita Kablinger, Bush Kavuru. Transient agranulocytosis associated with ziprasidone in a 45-year-old man on hemodialysis.
Journal of clinical psychopharmacology.
2015 Jun; 35(3):347-8. doi:
10.1097/jcp.0000000000000324. [PMID: 25874914] - Piotr Tybura, Beata Trześniowska-Drukała, Przemyslaw Bienkowski, Aleksander Beszlej, Dorota Frydecka, Pawel Mierzejewski, Agnieszka Samochowiec, Anna Grzywacz, Jerzy Samochowiec. Pharmacogenetics of adverse events in schizophrenia treatment: comparison study of ziprasidone, olanzapine and perazine.
Psychiatry research.
2014 Oct; 219(2):261-7. doi:
10.1016/j.psychres.2014.05.039. [PMID: 24930580] - Rocio Pérez-Iglesias, Victor Ortiz-Garcia de la Foz, Obdulia Martínez García, Jose Antonio Amado, M Teresa Garcia-Unzueta, Rosa Ayesa-Arriola, Paula Suarez-Pinilla, Rafael Tabares-Seisdedos, Benedicto Crespo-Facorro. Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12 weeks of treatment in first treated episode of psychosis.
Schizophrenia research.
2014 Oct; 159(1):90-4. doi:
10.1016/j.schres.2014.07.045. [PMID: 25151200] - Mona Darwish, Mary Bond, Ronghua Yang, Edward T Hellriegel, Philmore Robertson. Evaluation of the potential for a pharmacokinetic drug-drug interaction between armodafinil and ziprasidone in healthy adults.
Clinical drug investigation.
2014 Oct; 34(10):691-9. doi:
10.1007/s40261-014-0220-3. [PMID: 25047407] - Pierre Chue, Francine S Mandel, François Therrien. The effect of ziprasidone on metabolic syndrome risk factors in subjects with schizophrenia: a 1 year, open-label, prospective study.
Current medical research and opinion.
2014 Jun; 30(6):997-1005. doi:
10.1185/03007995.2014.898139. [PMID: 24568177] - Laura Mercolini, Roberto Mandrioli, Michele Protti, Andreas Conca, Lawrence J Albers, Maria Augusta Raggi. Dried blood spot testing: a novel approach for the therapeutic drug monitoring of ziprasidone-treated patients.
Bioanalysis.
2014 Jun; 6(11):1487-95. doi:
10.4155/bio.14.3. [PMID: 25046049] - Laura Mercolini, Michele Protti, Giulia Fulgenzi, Roberto Mandrioli, Nadia Ghedini, Andreas Conca, Maria Augusta Raggi. A fast and feasible microextraction by packed sorbent (MEPS) procedure for HPLC analysis of the atypical antipsychotic ziprasidone in human plasma.
Journal of pharmaceutical and biomedical analysis.
2014 Jan; 88(?):467-71. doi:
10.1016/j.jpba.2013.09.019. [PMID: 24176751] - Hwang-Bin Lee, Bo-Hyun Yoon, Young-Joon Kwon, Young Sup Woo, Jung-Goo Lee, Moon-Doo Kim, Won-Myong Bahk. The efficacy and safety of switching to ziprasidone from olanzapine in patients with bipolar I disorder: an 8-week, multicenter, open-label study.
Clinical drug investigation.
2013 Oct; 33(10):743-53. doi:
10.1007/s40261-013-0120-y. [PMID: 23990283] - Sho Moriguchi, Robert R Bies, Gary Remington, Takefumi Suzuki, David C Mamo, Koichiro Watanabe, Masaru Mimura, Bruce G Pollock, Hiroyuki Uchida. Estimated dopamine D₂ receptor occupancy and remission in schizophrenia: analysis of the CATIE data.
Journal of clinical psychopharmacology.
2013 Oct; 33(5):682-5. doi:
10.1097/jcp.0b013e3182979a0a. [PMID: 23899638] - Takashi Tsuboi, Robert R Bies, Takefumi Suzuki, David C Mamo, Bruce G Pollock, Ariel Graff-Guerrero, Masaru Mimura, Hiroyuki Uchida. Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data.
Progress in neuro-psychopharmacology & biological psychiatry.
2013 Aug; 45(?):178-82. doi:
10.1016/j.pnpbp.2013.05.010. [PMID: 23727135] - Donald C Goff, Joseph P McEvoy, Leslie Citrome, Arnold W Mech, Juan R Bustillo, Roberto Gil, Peter Buckley, Theo C Manschreck, Eric D Achtyes, Eric A Macklin. High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: the ZEBRAS study.
Journal of clinical psychopharmacology.
2013 Aug; 33(4):485-90. doi:
10.1097/jcp.0b013e3182977308. [PMID: 23775057] - D Holthoewer, K M Kirschbaum, J Frisch, C Hiemke, U Schmitt. Pharmacodynamic effects of aripiprazole and ziprasidone with respect to p-glycoprotein substrate properties.
Pharmacopsychiatry.
2013 Jul; 46(5):175-80. doi:
10.1055/s-0033-1347176. [PMID: 23737243] - Anna Dietrich-Muszalska, Justyna Kopka, Anna Kwiatkowska. The effects of ziprasidone, clozapine and haloperidol on lipid peroxidation in human plasma (in vitro): comparison.
Neurochemical research.
2013 Jul; 38(7):1490-5. doi:
10.1007/s11064-013-1050-z. [PMID: 23619559] - Hitoshi Sakurai, Robert R Bies, Scott T Stroup, Richard S E Keefe, Tarek K Rajji, Takefumi Suzuki, David C Mamo, Bruce G Pollock, Koichiro Watanabe, Masaru Mimura, Hiroyuki Uchida. Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data.
Schizophrenia bulletin.
2013 May; 39(3):564-74. doi:
10.1093/schbul/sbr189. [PMID: 22290266] - Ping Shao, Jianjun Ou, Renrong Wu, Maosheng Fang, Honghui Chen, Yi Xu, Jingping Zhao. [Effects of ziprasidone and olanzapine on glucose and lipid metabolism in first-episode schizophrenia].
Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences.
2013 Apr; 38(4):365-9. doi:
10.3969/j.issn.1672-7347.2013.04.005. [PMID: 23645236] - Jian-Jun Ou, Yi Xu, Hong-Hui Chen, Xiaoduo Fan, Keming Gao, Juan Wang, Xiao-Feng Guo, Ren-Rong Wu, Jing-Ping Zhao. Comparison of metabolic effects of ziprasidone versus olanzapine treatment in patients with first-episode schizophrenia.
Psychopharmacology.
2013 Feb; 225(3):627-35. doi:
10.1007/s00213-012-2850-6. [PMID: 22926006] - Andrew J Cutler, Amir H Kalali, Greg W Mattingly, Jelena Kunovac, Xiangyi Meng. Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial.
CNS spectrums.
2013 Feb; 18(1):43-54. doi:
10.1017/s1092852912000764. [PMID: 23312567] - David N Osser, Mohsen Jalali Roudsari, Theo Manschreck. The psychopharmacology algorithm project at the Harvard South Shore Program: an update on schizophrenia.
Harvard review of psychiatry.
2013 Jan; 21(1):18-40. doi:
10.1097/hrp.0b013e31827fd915. [PMID: 23656760] - Priscila Gubert, Gabriel Costa Aguiar, Tácito Mourão, Jessika Cristina Bridi, Alexandre Guimarães Barros, Félix Alexandre Soares, Marco Aurélio Romano-Silva. Behavioral and metabolic effects of the atypical antipsychotic ziprasidone on the nematode Caenorhabditis elegans.
PloS one.
2013; 8(9):e74780. doi:
10.1371/journal.pone.0074780. [PMID: 24069346] - Yinbo Zhang, Guangzhi Dai. Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China.
Human psychopharmacology.
2012 Nov; 27(6):605-14. doi:
10.1002/hup.2270. [PMID: 24446539] - Swapnil Marghade, Prashant B Musmade, Sudheer Moorkoth. High-performance liquid chromatographic assay for ziprasidone in plasma samples: application to pharmacokinetic studies in rats.
Journal of chromatographic science.
2012 Nov; 50(10):902-8. doi:
10.1093/chromsci/bms088. [PMID: 22677485] - Rui-Ming Li, Cong Wang, Zhi-Wei Liu, Bin Zhao. A case of severe hyponatremia induced by duloxetine and ziprasidone.
Chinese medical journal.
2012 Oct; 125(20):3750-1. doi:
. [PMID: 23075738] - Tong Zhao, Tae-Won Park, Jong-Chul Yang, Guang-Biao Huang, Min-Gul Kim, Keon-Hak Lee, Young-Chul Chung. Efficacy and safety of ziprasidone in the treatment of first-episode psychosis: an 8-week, open-label, multicenter trial.
International clinical psychopharmacology.
2012 Jul; 27(4):184-90. doi:
10.1097/yic.0b013e3283528d22. [PMID: 22426471] - Elizabeth Pappadopulos, John W Newcomer, Sheela Kolluri. Changes in weight, plasma lipids, and glucose in adults treated with ziprasidone: a comprehensive analysis of pfizer-initiated clinical trials.
The Journal of clinical psychiatry.
2012 Jun; 73(6):e742-8. doi:
10.4088/jcp.10r06802. [PMID: 22795213] - X L Wu, J H Wang, S H Hu, J Tao. Serum prolactin levels and the acute-phase efficacy in drug-naïve schizophrenia treated with ziprasidone and olanzapine (translated version).
East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan.
2012 Mar; 22(1):7-11. doi:
NULL. [PMID: 22447799] - Vance L Albaugh, Thomas C Vary, Olga Ilkayeva, Brett R Wenner, Kevin P Maresca, John L Joyal, Steven Breazeale, Tedd D Elich, Charles H Lang, Christopher J Lynch. Atypical antipsychotics rapidly and inappropriately switch peripheral fuel utilization to lipids, impairing metabolic flexibility in rodents.
Schizophrenia bulletin.
2012 Jan; 38(1):153-66. doi:
10.1093/schbul/sbq053. [PMID: 20494946] - Tae-Sung Koo, Soo-Jin Kim, Jongjoo Lee, Dong-Jin Ha, Myoungki Baek, Hongsik Moon. Quantification of lurasidone, an atypical antipsychotic drug, in rat plasma with high-performance liquid chromatography with tandem mass spectrometry.
Biomedical chromatography : BMC.
2011 Dec; 25(12):1389-94. doi:
10.1002/bmc.1625. [PMID: 21387355] - Kyeong-Ryoon Lee, Yoon-Jee Chae, Tae-Sung Koo. Pharmacokinetics of lurasidone, a novel atypical anti-psychotic drug, in rats.
Xenobiotica; the fate of foreign compounds in biological systems.
2011 Dec; 41(12):1100-7. doi:
10.3109/00498254.2011.603388. [PMID: 21838595] - Andréa L Sertié, Angela May Suzuki, Rogério A L Sertié, Sandra Andreotti, Fábio B Lima, Maria Rita Passos-Bueno, Wagner F Gattaz. Effects of antipsychotics with different weight gain liabilities on human in vitro models of adipose tissue differentiation and metabolism.
Progress in neuro-psychopharmacology & biological psychiatry.
2011 Dec; 35(8):1884-90. doi:
10.1016/j.pnpbp.2011.07.017. [PMID: 21840366] - Christoph U Correll, Johnny D Lops, Vicki Figen, Anil K Malhotra, John M Kane, Peter Manu. QT interval duration and dispersion in children and adolescents treated with ziprasidone.
The Journal of clinical psychiatry.
2011 Jun; 72(6):854-60. doi:
10.4088/jcp.10m05990yel. [PMID: 21457682] - W Gordon Frankle, Ilise Lombardo, Lawrence S Kegeles, Mark Slifstein, John H Martin, Yiyun Huang, Dah-Ren Hwang, Elisa Reich, Claudine Cangiano, Roberto Gil, Anissa Abi-Dargham, Marc Laruelle. Measurement of the serotonin 1A receptor availability in patients with schizophrenia during treatment with the antipsychotic medication ziprasidone.
Journal of psychopharmacology (Oxford, England).
2011 Jun; 25(6):734-43. doi:
10.1177/0269881110388329. [PMID: 21109614] - Onur N Karayal, Paul Glue, Mary Bachinsky, Michelle Stewart, Phillip Chappell, Sheela Kolluri, Idil Cavus. Switching from quetiapine to ziprasidone: a sixteen-week, open-label, multicenter study evaluating the effectiveness and safety of ziprasidone in outpatient subjects with schizophrenia or schizoaffective disorder.
Journal of psychiatric practice.
2011 Mar; 17(2):100-9. doi:
10.1097/01.pra.0000396061.05269.c8. [PMID: 21430488] - Jørgen Hasselstrøm. Quantification of antidepressants and antipsychotics in human serum by precipitation and ultra high pressure liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2011 Jan; 879(1):123-8. doi:
10.1016/j.jchromb.2010.11.024. [PMID: 21163713] - M Soledad García, Joaquín A Ortuño, María Cuartero, Mustafa Salem Abuherba. Use of a new ziprasidone-selective electrode in mixed solvents and its application in the analysis of pharmaceuticals and biological fluids.
Sensors (Basel, Switzerland).
2011; 11(9):8813-25. doi:
10.3390/s110908813. [PMID: 22164107] - Hongying Gao, Shibing Deng, R Scott Obach. A simple liquid chromatography-tandem mass spectrometry method to determine relative plasma exposures of drug metabolites across species for metabolite safety assessments.
Drug metabolism and disposition: the biological fate of chemicals.
2010 Dec; 38(12):2147-56. doi:
10.1124/dmd.110.034637. [PMID: 20847138] - Raymond A Lorenz, Cherry W Jackson, Marianne Saitz. Adjunctive use of atypical antipsychotics for treatment-resistant generalized anxiety disorder.
Pharmacotherapy.
2010 Sep; 30(9):942-51. doi:
10.1592/phco.30.9.942. [PMID: 20795849] - E N Rizos, S Chatziioannou, N Siafakas, A Douzenis, E Katsantoni, A Mandrapilia, S Bacalis, C Fotiadis, L Lykouras. Increased striatal dopamine transporter levels, as indicated by a DAT scan, induced by ziprasidone in association to improvement of tardive dyskinesia--a case report.
Progress in neuro-psychopharmacology & biological psychiatry.
2010 Aug; 34(6):1135-6. doi:
10.1016/j.pnpbp.2010.05.001. [PMID: 20460141] - Dilek Kul, Mehmet Gumustas, Bengi Uslu, Sibel A Ozkan. Electroanalytical characteristics of antipsychotic drug ziprasidone and its determination in pharmaceuticals and serum samples on solid electrodes.
Talanta.
2010 Jun; 82(1):286-95. doi:
10.1016/j.talanta.2010.04.036. [PMID: 20685469] - Vasilios G Masdrakis, Andreas Florakis, Georgios Tzanoulinos, Maria Markatou, Panagiotis Oulis. Safety of the electroconvulsive therapy-ziprasidone combination.
The journal of ECT.
2010 Jun; 26(2):139-42. doi:
10.1097/yct.0b013e3181c1880e. [PMID: 20386116] - Chip Gresham, Anne M Ruha. Respiratory failure following isolated ziprasidone ingestion in a toddler.
Journal of medical toxicology : official journal of the American College of Medical Toxicology.
2010 Mar; 6(1):41-3. doi:
10.1007/s13181-010-0035-4. [PMID: 20213216] - Jeffrey J Miceli, Thomas G Tensfeldt, Thomas Shiovitz, Richard Anziano, Cedric O'Gorman, Rachel H Harrigan. Effects of Oral Ziprasidone and Oral Haloperidol on QTc interval in patients with Schizophrenia or Schizoaffective disorder.
Pharmacotherapy.
2010 Feb; 30(2):127-35. doi:
10.1592/phco.30.2.127. [PMID: 20099987] - Guang-fa Wang, Qing-xia Chen, Wei-qiao Huang, Wei-zhong Liu, Jia-jie Zhang. [Pharmacokinetics and relative bioavailability of ziprasidone tablets in Chinese healthy volunteers].
Nan fang yi ke da xue xue bao = Journal of Southern Medical University.
2009 Aug; 29(8):1561-4. doi:
NULL. [PMID: 19726292] - Gerald M Reaven, Jeffrey A Lieberman, Gopalan Sethuraman, Helena Kraemer, John M Davis, Christine Blasey, Ming T Tsuang, Alan F Schatzberg. In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment.
Journal of psychiatric research.
2009 Jul; 43(11):997-1002. doi:
10.1016/j.jpsychires.2009.01.010. [PMID: 19268968] - Mathias Zink, A Kuwilsky, B Krumm, H Dressing. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial.
Journal of psychopharmacology (Oxford, England).
2009 May; 23(3):305-14. doi:
10.1177/0269881108089593. [PMID: 18562423] - Friederike Vogel, Reinhard Gansmüller, Thomas Leiblein, Otto Dietmaier, Hans Wassmuth, Gerhard Gründer, Christoph Hiemke. The use of ziprasidone in clinical practice: analysis of pharmacokinetic and pharmacodynamic aspects from data of a drug monitoring survey.
European psychiatry : the journal of the Association of European Psychiatrists.
2009 Apr; 24(3):143-8. doi:
10.1016/j.eurpsy.2008.09.003. [PMID: 18950992] - Ingo Vernaleken, Christine Fellows, Hildegard Janouschek, Anno Bröcheler, Tanja Veselinovic, Christian Landvogt, Christian Boy, Hans-Georg Buchholz, Katja Spreckelmeyer, Peter Bartenstein, Paul Cumming, Christoph Hiemke, Frank Rösch, Wolfgang Schäfer, Dean F Wong, Gerhard Gründer. Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone).
Journal of clinical psychopharmacology.
2008 Dec; 28(6):608-17. doi:
10.1097/jcp.0b013e31818ba2f6. [PMID: 19011428] - Maria D Chermá, Margareta Reis, Staffan Hägg, Johan Ahlner, Finn Bengtsson. Therapeutic drug monitoring of ziprasidone in a clinical treatment setting.
Therapeutic drug monitoring.
2008 Dec; 30(6):682-8. doi:
10.1097/ftd.0b013e31818ac8ba. [PMID: 18824954] - Marie-Bernadette Assié, Elisabeth Carilla-Durand, Laurent Bardin, Mireille Maraval, Monique Aliaga, Nathalie Malfètes, Michèle Barbara, Adrian Newman-Tancredi. The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063.
European journal of pharmacology.
2008 Sep; 592(1-3):160-6. doi:
10.1016/j.ejphar.2008.06.105. [PMID: 18640111] - Jonathan M Meyer, Vicki G Davis, Joseph P McEvoy, Donald C Goff, Henry A Nasrallah, Sonia M Davis, Gail L Daumit, John Hsiao, Marvin S Swartz, T Scott Stroup, Jeffrey A Lieberman. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.
Schizophrenia research.
2008 Aug; 103(1-3):104-9. doi:
10.1016/j.schres.2008.04.023. [PMID: 18534821] - Guodong Zhang, Alvin V Terry, Michael G Bartlett. Determination of the lipophilic antipsychotic drug ziprasidone in rat plasma and brain tissue using liquid chromatography-tandem mass spectrometry.
Biomedical chromatography : BMC.
2008 Jul; 22(7):770-8. doi:
10.1002/bmc.999. [PMID: 18318016] - Peter J Weiden, John W Newcomer, Antony D Loebel, Ruoyong Yang, Harold E Lebovitz. Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.
2008 Apr; 33(5):985-94. doi:
10.1038/sj.npp.1301482. [PMID: 17637612] - Qian Bian, Takahiro Kato, Akira Monji, Sadayuki Hashioka, Yoshito Mizoguchi, Hideki Horikawa, Shigenobu Kanba. The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-gamma.
Progress in neuro-psychopharmacology & biological psychiatry.
2008 Jan; 32(1):42-8. doi:
10.1016/j.pnpbp.2007.06.031. [PMID: 17716796] - Guodong Zhang, Alvin V Terry, Michael G Bartlett. Sensitive liquid chromatography/tandem mass spectrometry method for the simultaneous determination of olanzapine, risperidone, 9-hydroxyrisperidone, clozapine, haloperidol and ziprasidone in rat brain tissue.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2007 Oct; 858(1-2):276-81. doi:
10.1016/j.jchromb.2007.08.007. [PMID: 17766202] - M J Fell, N Anjum, K Dickinson, K M Marshall, L M Peltola, S Vickers, S Cheetham, J C Neill. The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats.
Psychopharmacology.
2007 Oct; 194(2):221-31. doi:
10.1007/s00213-007-0833-9. [PMID: 17581744] - Albert K K Chung, Siew-eng Chua. Acute urinary retention associated with selective serotonin reuptake inhibitors and ziprasidone.
Journal of clinical psychopharmacology.
2007 Oct; 27(5):517-9. doi:
10.1097/jcp.0b013e318150c80e. [PMID: 17873690] - J Minet-Ringuet, P C Even, P Valet, C Carpéné, V Visentin, D Prévot, D Daviaud, A Quignard-Boulange, D Tomé, R de Beaurepaire. Alterations of lipid metabolism and gene expression in rat adipocytes during chronic olanzapine treatment.
Molecular psychiatry.
2007 Jun; 12(6):562-71. doi:
10.1038/sj.mp.4001948. [PMID: 17211438] - M C Mauri, A Colasanti, M Rossattini, L S Volonteri, F Dragogna, A Fiorentini, A Fiorentini, A Valli, P Papa. Ziprasidone outcome and tolerability: a practical clinical trial with plasma drug levels.
Pharmacopsychiatry.
2007 May; 40(3):89-92. doi:
10.1055/s-2007-973835. [PMID: 17541882] - Patrick M Garman, L Douglas Ried, Michael A Bengtson, Chienning Hsu, Joel R McConkey. Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia.
Journal of the American Pharmacists Association : JAPhA.
2007 May; 47(3):373-8. doi:
10.1331/japha.2007.06090. [PMID: 17510032] - Duerten Kudla, Martin Lambert, Sabine Domin, Siegfried Kasper, Dieter Naber. Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: results of a multi-centre observational trial.
European psychiatry : the journal of the Association of European Psychiatrists.
2007 Apr; 22(3):195-202. doi:
10.1016/j.eurpsy.2006.06.004. [PMID: 17140769] - José Manuel Montes, Jose Luis Rodriguez, Eduardo Balbo, Pedro Sopelana, Eloy Martin, Jose Antonio Soto, Jose Francisco Delgado, Teresa Diez, Inmaculada Villardaga. Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone.
Progress in neuro-psychopharmacology & biological psychiatry.
2007 Mar; 31(2):383-8. doi:
10.1016/j.pnpbp.2006.10.002. [PMID: 17129654] - Manickam Aravagiri, Stephen R Marder, Bruce Pollock. Determination of ziprasidone in human plasma by liquid chromatography-electrospray tandem mass spectrometry and its application to plasma level determination in schizophrenia patients.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2007 Mar; 847(2):237-44. doi:
10.1016/j.jchromb.2006.10.024. [PMID: 17098485] - Jeffrey J Miceli, Paul Glue, Jeffrey Alderman, Keith Wilner. The effect of food on the absorption of oral ziprasidone.
Psychopharmacology bulletin.
2007; 40(3):58-68. doi:
NULL. [PMID: 18007569] - Christoph U Correll, Anne M Frederickson, John M Kane, Peter Manu. Does antipsychotic polypharmacy increase the risk for metabolic syndrome?.
Schizophrenia research.
2007 Jan; 89(1-3):91-100. doi:
10.1016/j.schres.2006.08.017. [PMID: 17070017] - Maria A Rettenbacher, Christoph Ebenbichler, Alex Hofer, Georg Kemmler, Susanne Baumgartner, Monika Edlinger, Martina Hummer, Monika Lechleitner, W Wolfgang Fleischhacker. Early changes of plasma lipids during treatment with atypical antipsychotics.
International clinical psychopharmacology.
2006 Nov; 21(6):369-72. doi:
10.1097/01.yic.0000224786.75664.3b. [PMID: 17012984] - Hsiao-Lun Ku, Tung-Ping Su, Yuan-Hwa Chou. Ziprasidone-associated pedal edema in the treatment of schizophrenia.
Progress in neuro-psychopharmacology & biological psychiatry.
2006 Jul; 30(5):963-4. doi:
10.1016/j.pnpbp.2006.01.020. [PMID: 16624468] - Marcio Versiani. Ziprasidone in bipolar disorder.
Expert opinion on pharmacotherapy.
2006 Jun; 7(9):1221-8. doi:
10.1517/14656566.7.9.1221. [PMID: 16732708] - Floyd R Sallee, Jeffrey J Miceli, Thomas Tensfeldt, Lisa Robarge, Keith Wilner, Nick C Patel. Single-dose pharmacokinetics and safety of ziprasidone in children and adolescents.
Journal of the American Academy of Child and Adolescent Psychiatry.
2006 Jun; 45(6):720-728. doi:
10.1097/01.chi.0000215347.93902.3e. [PMID: 16721322] - Mikhail Kalinichev, Claire Rourke, Declan N C Jones. Body weights and plasma prolactin levels in female rats treated subchronically with ziprasidone versus olanzapine.
Behavioural pharmacology.
2006 May; 17(3):289-92. doi:
10.1097/00008877-200605000-00009. [PMID: 16572006] - Osama Y Al-Dirbashi, Hassan Y Aboul-Enein, Ahmed Al-Odaib, Minnie Jacob, Mohamed S Rashed. Rapid liquid chromatography-tandem mass spectrometry method for quantification of ziprasidone in human plasma.
Biomedical chromatography : BMC.
2006 Apr; 20(4):365-8. doi:
10.1002/bmc.571. [PMID: 16167302] - Chanoch Miodownik, Michael Hausmann, Katherina Frolova, Vladimir Lerner. Lithium intoxication associated with intramuscular ziprasidone in schizoaffective patients.
Clinical neuropharmacology.
2005 Nov; 28(6):295-7. doi:
10.1097/01.wnf.0000194037.75621.78. [PMID: 16340388] - Alan Breier, Paul H Berg, Jogin H Thakore, Dieter Naber, Wagner F Gattaz, Patrizia Cavazzoni, Daniel J Walker, Suraja M Roychowdhury, John M Kane. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia.
The American journal of psychiatry.
2005 Oct; 162(10):1879-87. doi:
10.1176/appi.ajp.162.10.1879. [PMID: 16199834] - Jeffrey A Lieberman, T Scott Stroup, Joseph P McEvoy, Marvin S Swartz, Robert A Rosenheck, Diana O Perkins, Richard S E Keefe, Sonia M Davis, Clarence E Davis, Barry D Lebowitz, Joanne Severe, John K Hsiao. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
The New England journal of medicine.
2005 Sep; 353(12):1209-23. doi:
10.1056/nejmoa051688. [PMID: 16172203] - E Baca, J R Azanza, J Giner, J Saiz-Ruiz, J Vallejo, T Diez, M Madrigal. Ziprasidone: from pharmacology to the clinical practice. One year of experience.
Actas espanolas de psiquiatria.
2005 Sep; 33(5):311-24. doi:
. [PMID: 16155814] - Dan L Zimbroff, Michael H Allen, John Battaglia, Leslie Citrome, Avrim Fishkind, Andrew Francis, Daniel L Herr, Douglas Hughes, Marc Martel, Horacio Preval, Ruth Ross. Best clinical practice with ziprasidone IM: update after 2 years of experience.
CNS spectrums.
2005 Sep; 10(9):1-15. doi:
10.1017/s1092852900025487. [PMID: 16247923] - Andreas Meier, Anna-Catharina Neumann, Wolfgang Jordan, Gerald Huether, Andrea Rodenbeck, Eckart Rüther, Stefan Cohrs. Ziprasidone decreases cortisol excretion in healthy subjects.
British journal of clinical pharmacology.
2005 Sep; 60(3):330-6. doi:
10.1111/j.1365-2125.2005.02431.x. [PMID: 16120074] - Jeffrey J Miceli, Keith D Wilner, Suzanne K Swan, Thomas G Tensfeldt. Pharmacokinetics, safety, and tolerability of intramuscular ziprasidone in healthy volunteers.
Journal of clinical pharmacology.
2005 Jun; 45(6):620-30. doi:
10.1177/0091270005276485. [PMID: 15901743] - M J Fell, R Gibson, E McDermott, G Sisodia, K M Marshall, J C Neill. Investigation into the effects of the novel antipsychotic ziprasidone on weight gain and reproductive function in female rats.
Behavioural brain research.
2005 May; 160(2):338-43. doi:
10.1016/j.bbr.2004.12.015. [PMID: 15863230] - Julia Sachse, Sebastian Härtter, Christoph Hiemke. Automated determination of ziprasidone by HPLC with column switching and spectrophotometric detection.
Therapeutic drug monitoring.
2005 Apr; 27(2):158-62. doi:
10.1097/01.ftd.0000150879.36296.4d. [PMID: 15795645] - Ronald R Brown, Michael W Estoup. Comparison of the metabolic effects observed in patients treated with ziprasidone versus olanzapine.
International clinical psychopharmacology.
2005 Mar; 20(2):105-12. doi:
10.1097/00004850-200503000-00008. [PMID: 15729087] - Philip D Harvey, Christopher R Bowie. Ziprasidone: efficacy, tolerability, and emerging data on wide-ranging effectiveness.
Expert opinion on pharmacotherapy.
2005 Feb; 6(2):337-46. doi:
10.1517/14656566.6.2.337. [PMID: 15757429] - Miloslav Kopecek, Martin Bares, Pavel Mohr. Ziprasidone-induced galactorrhea: a case report.
Neuro endocrinology letters.
2005 Feb; 26(1):69-70. doi:
NULL. [PMID: 15726024] - Sheldon H Preskorn. Pharmacokinetics and therapeutics of acute intramuscular ziprasidone.
Clinical pharmacokinetics.
2005; 44(11):1117-33. doi:
10.2165/00003088-200544110-00002. [PMID: 16231965]